Protalix BioTherapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $80.6M+51.0% YoYTTM through 30 Jun 2026
Net Income $18.9M+546.1% YoYTTM through 30 Jun 2026
Free Cash Flow $7.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 48.9% |
| EBITDA Margin | 30.6% |
| Operating Margin | -10.4% |
| Net Margin | 23.5% |
Returns
-13.7%ROE
-8.0%ROA
43.1%ROIC
Balance Sheet Health
Debt / Equity0.00x
Current Ratio2.94x
Net Debt-$30.3Mnet cash position
Cash & Equivalents$27.4M
Quality Metrics
Altman Z-Score0.73
Piotroski F-Score4 / 9
FCF Margin9.5%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $52.7M
Diluted EPS$0.23TTMFY2025: $-0.08
Dividend
No dividend
Capital Allocation
R&D Spend$19.9M
Capex Intensity2.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Selling Goods | $51.8M | -2.3% | |
| License and R&D Services | $900K | +125.0% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.